Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 847.19
GLPGF's Cash to Debt is ranked higher than
81% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. GLPGF: 847.19 )
GLPGF' s 10-Year Cash to Debt Range
Min: 5.13   Max: No Debt
Current: 847.19

Equity to Asset 0.58
GLPGF's Equity to Asset is ranked higher than
68% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GLPGF: 0.58 )
GLPGF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.77
Current: 0.58

0.5
0.77
F-Score: 4
Z-Score: 1.94
M-Score: -4.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -15.81
GLPGF's Operating margin (%) is ranked higher than
77% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. GLPGF: -15.81 )
GLPGF' s 10-Year Operating margin (%) Range
Min: -59.16   Max: 1.78
Current: -15.81

-59.16
1.78
Net-margin (%) 39.99
GLPGF's Net-margin (%) is ranked higher than
98% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. GLPGF: 39.99 )
GLPGF' s 10-Year Net-margin (%) Range
Min: -58.19   Max: 3.57
Current: 39.99

-58.19
3.57
ROE (%) 28.47
GLPGF's ROE (%) is ranked higher than
97% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. GLPGF: 28.47 )
GLPGF' s 10-Year ROE (%) Range
Min: -24.8   Max: 3.4
Current: 28.47

-24.8
3.4
ROA (%) 18.36
GLPGF's ROA (%) is ranked higher than
97% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. GLPGF: 18.36 )
GLPGF' s 10-Year ROA (%) Range
Min: -18.65   Max: 2.59
Current: 18.36

-18.65
2.59
ROC (Joel Greenblatt) (%) -132.55
GLPGF's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. GLPGF: -132.55 )
GLPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -141.5   Max: 6.87
Current: -132.55

-141.5
6.87
Revenue Growth (%) -1.80
GLPGF's Revenue Growth (%) is ranked higher than
74% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GLPGF: -1.80 )
GLPGF' s 10-Year Revenue Growth (%) Range
Min: -1.8   Max: 39.9
Current: -1.8

-1.8
39.9
EPS Growth (%) 110.50
GLPGF's EPS Growth (%) is ranked higher than
99% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. GLPGF: 110.50 )
GLPGF' s 10-Year EPS Growth (%) Range
Min: -69.5   Max: 110.5
Current: 110.5

-69.5
110.5
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.17
GLPGF's P/B is ranked higher than
89% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. GLPGF: 2.17 )
GLPGF' s 10-Year P/B Range
Min: 0.61   Max: 4.25
Current: 2.17

0.61
4.25
P/S 2.55
GLPGF's P/S is ranked higher than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. GLPGF: 2.55 )
GLPGF' s 10-Year P/S Range
Min: 0.91   Max: 8.21
Current: 2.55

0.91
8.21
EV-to-EBIT -26.05
GLPGF's EV-to-EBIT is ranked higher than
67% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GLPGF: -26.05 )
GLPGF' s 10-Year EV-to-EBIT Range
Min: 40.5   Max: 128.7
Current: -26.05

40.5
128.7
Current Ratio 1.57
GLPGF's Current Ratio is ranked higher than
58% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. GLPGF: 1.57 )
GLPGF' s 10-Year Current Ratio Range
Min: 1.22   Max: 3.48
Current: 1.57

1.22
3.48
Quick Ratio 1.57
GLPGF's Quick Ratio is ranked higher than
61% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. GLPGF: 1.57 )
GLPGF' s 10-Year Quick Ratio Range
Min: 1.22   Max: 3.45
Current: 1.57

1.22
3.45

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) 0.45
GLPGF's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. GLPGF: 0.45 )
GLPGF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: -4.2
Current: 0.45

-9.6
-4.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, LSE:0Q4U, BIIB » details
Traded in other countries:0JXZ.country, GLPG.Belgium, GLPG.Netherlands, GXE.Germany
Galapagos NV is a clinical stage biotech company focused on developing novel medicines. The company operates in two business divisions, R&D and Services. It also offers contract research services in the areas of in vitro, biology, analytics, among others. R&D operations specialize in the discovery and development of small molecules. Service operations offer target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
» More Articles for OTCPK:GLPGF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
BUZZ-Galapagos at 6-mnth low on drug trial update Jun 17 2014
Galapagos to hold Annual R&D Update on 17 June 2014 in New York May 12 2014
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014 Apr 30 2014
Galapagos announces management change Apr 28 2014
Baker Brothers notify of 4.99% shareholding in Galapagos Apr 24 2014
Galapagos, GSK successfully conclude phase 2a study of skin disease drug Apr 17 2014
GSK2586184 met primary endpoint in Phase 2a psoriasis study Apr 17 2014
Galapagos raises €2.4 million through warrant exercises Apr 10 2014
Charles River Laboratories and Galapagos complete transaction Apr 01 2014
Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April... Mar 28 2014
Euronext Amsterdam to become Market of Reference for Galapagos Mar 21 2014
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase... Mar 18 2014
Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV Mar 13 2014
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to... Mar 13 2014
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative... Mar 10 2014
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD Mar 10 2014
Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis... Mar 10 2014
Galapagos receives €2 million from osteoarthritis alliance with Servier Mar 10 2014
Galapagos reports 2013 financial results Mar 10 2014
Galapagos reports 2013 financial results Mar 07 2014
Galapagos receives €2 million from osteoarthritis alliance with Servier Mar 07 2014
Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis... Feb 28 2014
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD Feb 21 2014
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative... Feb 17 2014
Galapagos receives €2.3 million IWT grant for fibrosis research Feb 03 2014
First clinical centers opened for Phase 2 Crohn's study with GLPG0634 Jan 29 2014
STOCKS NEWS EUROPE-Galapagos at 8-month high as UBS rates "buy" Jan 29 2014
Galapagos receives €2.9 million IWT grant for cystic fibrosis research Jan 13 2014
Will Amazon evolve into the biggest retailer in the world? Jan 11 2014
Van Herk Investments notify of 5.3% shareholding in Galapagos Jan 08 2014
Van Herk Investments notify of 5.3% shareholding in Galapagos Jan 06 2014
Galapagos selects pre-clinical candidate for cystic fibrosis Dec 19 2013
Galapagos selects pre-clinical candidate for cystic fibrosis Dec 16 2013
Galapagos increases share capital through warrant exercises Dec 06 2013
Galapagos increases share capital through warrant exercises Dec 06 2013
Galapagos reports positive Phase 1 results for GLPG1205 Dec 04 2013
Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis Nov 27 2013
Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with... Nov 20 2013
Galapagos business update Nov 15 2013
Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma Nov 12 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK